Who We Are
An independent health care consulting firm founded by Principals with many years of experience consulting and providing support for life sciences clients including pharmaceutical, biotechnology, device and diagnostic manufacturers, and payers.
Our Principals and Director have extensive experience in health policy working with federal clients including the U.S. Food and Drug Administration, the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE), and the Centers for Disease Control and Prevention.
Kim Heithoff, MPH, SCD
SENIOR SCIENTIFIC ADVISOR
Dr. Heithoff has over 20 year of experience in the pharmaceutical industry with companies such as Merck, Novartis, and Schering-Plough. He has extensive experience and knowledge in outcomes research and market access. He has worked across multiple therapy areas across the continuum of the product development life cycle. Of particular interest is the integration of health technology assessment requirements into the earliest phases of drug development and leveraging the clinical development program to mitigate risks to pricing and reimbursement. Areas of expertise include identification of value evidence needs and the strategic planning requirements around market access, health policy and strategic value evidence generation, and communication. He received both a Master of Public Health (MPH) and a Doctor of Science (ScD) from the Johns Hopkins University Bloomberg School of Public Health.
SENIOR SCIENTIFIC ADVISOR
Daniel Touchette is Professor and Director of Graduate Studies for the Masters in Comparative Effectiveness Research program at the University of Illinois at Chicago's College of Pharmacy. His primary research interests are evaluating the cost-effectiveness of pharmaceutical agents assessing the effectiveness and cost-effectiveness of clinical pharmacist and other health practitioner services, and developing and assessing methods for improving adherence to medication regimens. Dr. Touchette has obtained grant funding from AHRQ, NIH, and numerous foundations and other sources. Most recently, he has developed decision models for the Institute for Clinical and Economic Review (ICER) and leads UIC’s involvement in ICERs Health Economic Network. He has authored over 70 peer-reviewed manuscripts and reports.
Francine Chingcuanco's background is in epidemiology and pharmacology. Prior to joining Monument, she consulted for the Health Outcomes Research Department of Millennium Health wherein she designed and managed clinical research studies aimed at developing real-world evidence to support products in the field of personalized medicine. She holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Health as well as an Honours Bachelor of Science from the University of Toronto.
Omar Mansour specializes in the application of pharmacoepidemiology methods. Prior to joining Monument, he was a scholar at the Johns Hopkins Bloomberg School of Public Health’s Center for Drug Safety and Effectiveness where he designed and conducted comparative effectiveness studies on various topics using electronic medical records, commercial insurance claims, and large national surveys. He holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in biology with a minor in statistics from Macalester College.
Danyang Wang specializes in economic modeling and cost-effectiveness analysis. Before joining Monument Analytics she developed probabilistic Markov models to assess the cost-effectiveness of community health interventions while in training at Johns Hopkins Bloomberg School of Public Health. She holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Biology with a minor in Economics from Emory University.
Karen Dietz, MHS
Karen Dietz, MHS, Consultant, specializes in complex project management, outcomes research, and vaccines. Previously, she worked as a management consultant with enterprise clients across a variety of sectors, including life sciences and pharmaceutical industries. Karen has experience managing multiple outcomes-based research programs and clinical trials at the Johns Hopkins School of Medicine. Karen holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health, with a Certificate in Vaccine Science and Policy, and a Bachelor of Science from Virginia Tech.
Elena Fernandez, PharmD, PhD Candidate
Elena Fernandez specializes in pharmacoeconomics and health outcomes. She is a PhD candidate in the Department of Pharmacotherapy and Outcomes Sciences at Virginia Commonwealth University, where she designs and conducts research applying econometric models to evaluate opioid utilization in cancer survivors. Prior to her graduate training, she worked as a cancer research training award (CRTA) fellow at the National Cancer Institute. She holds a Doctor of Pharmacy from Virginia Commonwealth University and a Bachelor of Science in biochemistry from the University of Mary Washington.
Ellen Hu specializes in economic evaluation and has background in healthcare actuarial modeling. Prior to joining Monument, she worked in actuarial consulting where she performed valuations and projections for public and private employer sponsored retiree health plans as well as performed health plan rate settings and design modeling. She holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in Economics with a minor in Mathematics from DePauw University.
Shreena Malaviya specializes in health economics and modeling. Her background is in pharmacology and management. Previously, she worked as consultant internationally on projects such as building capacity in health economics, and analyzing the effectiveness and efficiency of health systems. She has also worked in reimbursement and risk management for specialty drug products. She holds a Masters in Health from Johns Hopkins Bloomberg school of Public Health and a Bachelor of Science from McGill University.
Divya Mohan’s background is in health economics and biomedical engineering. She specializes in patient preferences and cost-effectiveness analysis. Previously she worked at the Economist Intelligence Unit on projects including concept testing, communications strategy, market sizing, as well as customer perception and insight studies for imaging systems, in-vitro diagnostics, surgical devices, and procedures. She holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Healthand a Bachelor of Engineering from Nanyang Technological University.
Katharine Ozenberger specializes in epidemiology and pharmacoepidemiology. She is a PhD candidate in the Department of Pharmacy Systems, Outcomes, and Policy at the University of Illinois at Chicago where she designs and conducts research using longitudinal data from population-based cohorts, prescription dispensing, and commercial insurance claims. She holds a Masters in Science in epidemiology from the University of Illinois at Chicago's School of Public Health and a Bachelor of Science in biology from the University of Colorado Denver.
Emma Tassie specializes in economic evaluation and patient preferences. She is a PhD candidate in the Health Economics Research Unit (HERU), University of Aberdeen, where she is investigating the use of existing data to incorporate broader measures of benefit in economic evaluation. Prior to her PhD, Emma worked as a researcher at HERU where she conducted economic evaluations alongside randomized controlled trials and developed health economic models to accompany systematic reviews. She has a Masters in Science in Health Economics and a Bachelor of Arts (Economics and Sociology) from University College Cork
Jeromie Ballreich is an Assistant Scientist and Director of the Master of Health Sciences in Health Economics program in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health. He received his Ph.D. in Health Economics from Johns Hopkins Bloomberg School of Public Health with a thesis in “Price Discrimination in the US Cancer Drug Market.” Previously, Dr. Ballreich received a Master in Health Economics also from JHSPH and a Bachelors in Mathematics and Economics from Lafayette College.
Elisabeth H. Hazard
Dr. Hazard has over twenty years of experience working as a health care consultant. She was a founding leader of Value Medics Research, Inc. Her specialty is value development and value communications. She was an early pioneer in creating value development plans for medical technologies and facilitated the understanding of how demonstrations of economic value could be used effectively by product development and marketing teams. Dr. Hazard has worked with major pharmaceutical companies in the U.S. and Europe and on dozens of medical technologies.